Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

228.44 +1.61 (+0.71%)
Streaming Delayed Price Updated: 12:55 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
10 Biggest Price Target Changes For Monday ↗
Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. 
Via Benzinga
News headline image
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints ↗
Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in... 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts in March ↗
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
News headline image
Expert Ratings For Ascendis Pharma ↗
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
News headline image
Where Ascendis Pharma Stands With Analysts ↗
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Where Ascendis Pharma Stands With Analysts ↗
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
News headline image
Earnings Scheduled For March 2, 2022 ↗
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
Via Benzinga
News headline image
Analyst Ratings For Ascendis Pharma ↗
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
News headline image
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment ↗
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug. 
Via Investor's Business Daily
News headline image
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval ↗
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH).... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
News headline image
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks ↗
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP).... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price... 
Via Benzinga
News headline image
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript ↗
ASND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021 ↗
Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months ↗
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript ↗
ASND earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.